

ASX ANNOUNCEMENT

Quarterly Cashflow report

29th October 2015: Brisbane, Australia - Analytica Ltd (ASX: ALT) manufacturer of the PeriCoach® System, today released its Appendix 4C – Quarterly Cashflow report for the period ended 30 September 2015. The cash balance at 30 September 2015 was \$1,533k. PeriCoach® is a novel medical device to treat stress urinary incontinence – a condition with significant unmet medical need, affecting one in three women worldwide.

HIGHLIGHTS:

- Successful capital raising of \$2.9m
- Lodged 2015 R&D tax credit and expect receipt of \$1.9m in November
- Continued sales growth \$84k
- Continued progress with R&D for PeriCoach® \$402k
- Marketing and Sales launch in US including conference and social media US & Aust. \$614k
- Agreement with SalesForce4Hire to grow sales of PeriCoach® in the US
- US distribution agreement signed
- Increased sites and participants in the on-going clinical trial
- Appointment of Dr Thomas Lönngren as Non-Executive Director

During the quarter, Analytica made progress in its sales and marketing activities for its lead product, the PeriCoach® System, and the cash balance of \$1,533k supports these activities as well as continued R&D efforts for further enhancements of PeriCoach®.

In August, the Company conducted a successful capital raising of \$2.9m, with the proceeds being used to support Analytica's key commercialisation goals for PeriCoach®:

The Company achieved key milestones with US sales and marketing efforts in the quarter with the signing of a services agreement with SalesForce4Hire. SalesForce4Hire is a leading US commercialisation company and the agreement will help drive sales of PeriCoach® in the US market. The sales team commenced on October 1 and will focus on three US regions.

Analytica has a distribution agreement with US-based Current Technology Inc, a specialist distribution partner. Current Technology wholesale purchase PeriCoach® units and engage in marketing and sales activities across its extensive network, enhancing Analytica's own US-based distribution efforts.

In addition, the "Leakers Anonymous" video was launched as part of Analytica's US social media strategy and the campaign placed the video in front of 5.5 million blog subscribers, 250,000 Facebook followers and 170,000 Twitter followers.

PeriCoach® has continued to exhibit at major US and international urology and gynecology conferences and the response from specialists has been very supportive.

In Australia, sales continue to increase as we continue our direct-to-consumer and top-down marketing approach



of building awareness of the PeriCoach® System as an effective medical device with general practitioners and health professionals

Meanwhile, in our clinical trial being conducted in Australia, more trial sites were opened and the number of participants increased during the quarter.

Research and development of the pipeline of features for the PeriCoach® also continues to progress well.

During the quarter, Analytica lodged the 2015 R&D tax credit and expects a \$1.9mn receipt in November.

In August, Dr Thomas Lönngren was appointed as a Non-Executive Director. Dr Lönngren brings significant regulatory and strategic advisory experience and network in the pharmaceutical and medical device industries.

“This quarter has been another period of substantial progress for Analytica as we continue to focus on our commercialisation goals for PeriCoach® of building the best-in-class product, market acceptance and developing partnership opportunities with multinational medical device companies,” said Analytica Chief Executive Officer, Geoff Daly.

“Our agreements with SalesForce4Hire and Current Technology will help us drive sales in the US – a key market for Analytica while sales in Australia and post approval clinical trial also continue to progress well. ”

For more information please contact:

Geoff Daly, Chief Executive Officer on (07) 3278 1950

Kyahn Williamson, Investor Relations, Buchan Consulting on (03) 9866 4722

Gabriella Hold, Media Relations, Buchan Consulting on (03) 8866 1203

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:



About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition.

PeriCoach has regulatory clearance in Australia, and has CE mark clearance. The product has USFDA 510(k) clearance. The product has been on sale in Australia and New Zealand since January, and recently launched in the UK and Ireland, and in the USA. The US market for incontinence pads is \$5 billion pa. It is projected that by 2030, 5.6 million women in Australia will suffer urinary incontinence.



Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001

Name of entity

Analytica Limited

ABN

12 006 464 866

Quarter ended ("current quarter")

30/09/2015

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date (12 months) \$A'000
1.1 Receipts from customers	84	84
1.2 Payments for		
(a) staff costs	(361)	(361)
(b) advertising and marketing	(614)	(614)
(c) research and development	(402)	(402)
(d) leased assets	-	-
(e) other working capital	(252)	(252)
(f) realised currency gains	(23)	(23)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	5	5
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Other-		
(a) Net sales income	-	-
(b) R & D Tax Concession	-	-
(c) Royalty Income	-	-
(d) Other Grant Income	-	-
Net operating cash flows	(1,563)	(1,563)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

		Current quarter \$A'000	Year to date (12 months) \$A'000
1.8	Net operating cash flows (carried forward)	(1,563)	(1,563)
Cash flows related to investing activities			
1.9	Payment for acquisition of:		
	(a) businesses	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.10	Proceeds from disposal of:		
	(a) businesses	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.11	Loans to other entities	-	-
1.12	Loans repaid by other entities	-	-
1.13	Other (purchase of Convertible Notes)	-	-
	Net investing cash flows	-	-
1.14	Total operating and investing cash flows	1,563	1,563
Cash flows related to financing activities			
1.15	Proceeds from issues of shares	2,867	2,867
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from borrowings	-	-
1.18	Repayment of borrowings:	-	-
1.19	Dividends paid	-	-
1.20	Other Creditors (costs of fund raising)	(325)	(325)
	Net financing cash flows	2,542	2,542
	Net increase (decrease) in cash held	979	979
1.21	Cash at beginning of quarter/year to date	554	554
1.22	Exchange rate adjustments to item 1.20	-	-
1.23	Cash at end of quarter	1,533	1,533

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	110
1.25	Aggregate amount of loans to the parties included in item 1.11	-
1.26	Explanation necessary for an understanding of the transactions	
	Payment of director's fees and compulsory superannuation.	

Non-cash financing and investing activities

- 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

- 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	400	0
3.2	Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	1,533	554
4.2 Deposits at call	-	-
4.3 Bank overdraft	-	-
4.4 Other (provide details)	-	-
Total: cash at end of quarter (item 1.23)	1,533	554

Acquisitions and disposals of business entities

	Acquisitions	Disposals
5.1 Name of entity	N/A	N/A
5.2 Place of incorporation or registration		
5.3 Consideration for acquisition or disposal		
5.4 Total net assets		
5.5 Nature of business		

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here: Original signed

Date: 30 October 2015

Print name: Ross Mangelsdorf

+ See chapter 19 for defined terms.